A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Meanwhile, Boston Scientific is still waiting for antitrust regulators to conclude their review of its proposal to buy ...

Axonics (Nasdaq:AXNX) announced today that a jury unanimously ruled in its favor in a patent spat with (NYSE: MDT).

The Court for the Central District of California has sided with Axonics finding the company did not breach Medtronic’s ...

Continuous Glucose Monitoring (CGM) Systems Market The increasing incidence of diabetes and the detection of patient's blood glucose levels are raising the demand for continuous global monitoring ...

A jury unanimously found that Axonics did not infringe any of the three patents-in-suit brought against the company by Medtronic in a patent infringement lawsuit in the U.S. District Court for the ...

Axonics, Inc. (AXNX) comes out victorious in a patent trial against Medtronic (MDT), as the jury rules in its favor, awarding ...

Advanced materials are key to next-gen sensors, improving sensitivity and durability for critical applications in healthcare ...

New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.

MDT stock breaking above its 200 and 50-day SMAs can be a piece of good news for investors, signaling an uptrend.

Abbott integrated its FreeStyle Libre 2 Plus sensor with Tandem’s t:slim X2 insulin pump and Insulet received a CE mark for the integration of its Omnipod 5 pump with the company’s CGM. Abbott also ...